image description
image description

Archives


  • 11-11-16

    Jordan's Hikma faces lower full-year revenue

    (MENAFN) Hikma Pharmaceuticals Plc reduced its full-year revenue predictions for its generics business, due to slower ramp-up in the unit.Moreover, the firm bought U.S generic drugs business this year, proclaimed that its now predict full-year revenue from the business to reach USD600mn.Accordingly, it also said that it predicted full-year core operating profit from its generics unit to be hurt by a delay in approval of new products.In addition, the firm predicts full-year revenue to grow by 35 percent to almost USD2bn in constant currency.

Follow us

RSS
Terms & Conditions  |  Privacy & Security  |  Contact Us  | Sitemap
© 2024 BBK  |  All Rights Reserved